| Patient | James Madison |
|---|---|
| Date of birth | 1751-03-16 |
| Identifiers | MRN HR-EN007-SYN-TD; SSN (made up) 000-07-2618 |
| Document date | 1774-04-30 |
| Author | Josiah Pembroke-Achebe, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Discharge-day review after video-EEG monitoring; epilepsy and functional neurological disorder consultation today. [S]
Mr. Madison is seen on the morning of discharge after 72 hours of video-EEG monitoring. Two of his usual events were recorded, the second on the third evening after a night of sleep deprivation, and he confirmed on review of the video that both were typical. His MRI last week was normal. Dr. Okafor-Haverford of neurology reviewed the recordings with him yesterday and explained the diagnosis, and the neuropsychiatric assessment on the unit found generalized anxiety and a moderate depressive episode. He says he is relieved that it is not epilepsy, though he wonders how something that feels so real could come from the mind; he asked good questions and has read the written explanation. He has had no thoughts of death or self-harm, and the rifle has been locked away with the ammunition stored separately since his first visit. He has not driven since then. [S]
| Element | Detail |
|---|---|
| Video-EEG | Two habitual events captured; normal EEG throughout both |
| MRI | Normal |
| Mood and anxiety | PHQ-9 12; GAD-7 13 |
| Safety | No suicidal thoughts; rifle locked; not driving |
| System | Result | Finding |
|---|---|---|
| Constitutional | Positive | Tired after a night of sleep deprivation; no fever |
| Cardiovascular | Negative | No palpitations, chest pain, or exertional faintness |
| Neurological | Positive | Two recorded events; no headache, weakness, or numbness |
| Psychiatric | Positive | Low mood, worry, and irritability on levetiracetam; no suicidal thoughts, elevated mood, or psychotic symptoms |
4 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Levetiracetam 500 mg oral tablet, one tablet twice daily, started at an emergency department visit four months before intake for possible seizures, without an EEG | One tablet twice daily | Oral route | 1773-12-02 to 1774-04-30 | completed | S |
| Levetiracetam 500 mg oral tablet, taper: half a tablet (250 mg) twice daily for two weeks, then half a tablet at night for one week, then stop | Half a tablet twice daily for two weeks, then half a tablet at night for one week, then stop | Oral route | 1774-04-30 to 1774-05-21 | completed | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 1774-04-30 | Body height | 168 | cm | S |
| 1774-04-30 | Body weight | 54.2 | kg | S |
| 1774-04-30 | Body mass index (BMI) [Ratio] | 19.2 | kg/m2 | S |
| 1774-04-30 | Systolic blood pressure | 110 | mm[Hg] | S |
| 1774-04-30 | Diastolic blood pressure | 68 | mm[Hg] | S |
| 1774-04-30 | Heart rate | 72 | /min | S |
| 1774-04-30 | Respiratory rate | 14 | /min | S |
| 1774-04-30 | Body temperature | 36.6 | Cel | S |
| 1774-04-30 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 1774-04-30 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 12 | {score} | S | ||
| 1774-04-30 | Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ] | 13 | {score} | S |
Vital signs recorded on 1774-04-30; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Slight, tired, engaged |
| Neurological | Normal cranial nerves, strength, reflexes, coordination, and gait |
| Mental status | Mood "relieved but low"; affect constricted, brightening when discussing his studies; logical; no suicidal ideation; insight good |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Recurrent sudden episodes of unresponsiveness for two years, two or three a month: he 'blanks out', stops speaking, slumps or sinks to the floor with his eyes closed for two to ten minutes, and afterwards is tearful and tired, with no tongue biting, incontinence, or injury; first during a period of overwork and little sleep at college; with low mood and anxiety; unchanged on levetiracetam; under evaluation for epilepsy, functional (dissociative) seizures, syncope, and other causes | resolved | confirmed | R40.4 | S — Synthetic presenting problem echoing his documented overwork, infirm health, and low spirits, and the later accounts of sudden attacks; superseded by the diagnosis at the second visit. |
| Taking an antiseizure medicine (levetiracetam) started without a confirmed diagnosis of epilepsy | active | confirmed | Z79.899 | S — Synthetic medication problem for teaching about avoiding unneeded antiseizure medicines; resolved when the medicine was stopped. |
| Functional/dissociative seizures (psychogenic nonepileptic seizures), documented by video-EEG: two habitual events captured with eyes closed and resisting opening, fluctuating unresponsiveness, and a normal waking EEG throughout, with no ictal or postictal change; normal interictal EEG and brain MRI; epilepsy and syncope excluded | active | confirmed | F44.5 | S — Synthetic modern diagnosis. His infirm health, overwork, and low spirits in youth are documented (D); retrospective explanations of his later attacks, including epilepsy, are disputed (R). This record does not assert what his attacks were. |
| Generalized anxiety disorder: worry about his future, his health, and his studies most days for more than a year, with restlessness, poor sleep, and muscle tension (GAD-7 14 at intake) | active | confirmed | F41.1 | S — Synthetic diagnosis made at the neuropsychiatric assessment during video-EEG monitoring. |
| Major depressive disorder, single episode, moderate: low mood, loss of interest, poor sleep and concentration, and a sense that he will not live long, for about eighteen months (PHQ-9 13 at intake); no suicidal ideation or intent | active | confirmed | F32.1 | S — Synthetic diagnosis echoing, without asserting, his documented letter expecting an early death. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Survey | PHQ-9 | Baseline, then at least monthly during acute treatment; every 2 to 4 weeks in continuation | Completed today | 12, down from 13; item 9 scored 0 |
| Survey | GAD-7 | With the PHQ-9 when anxiety accompanies depression | Completed today | 13, down from 14 |
| Survey | Suicide risk reassessment (C-SSRS Since Last Visit and PHQ-9 item 9) | Every visit during active treatment | Completed today | No suicidal thoughts, intent, plan, or behavior; rifle locked with ammunition separate; protective factors unchanged |
| Survey | Bipolar screen at the initial depression workup | Once, at the initial workup | Completed today | No past manic or hypomanic episode on interview; no Mood Disorder Questionnaire score recorded |
| Imaging | Video-EEG monitoring to capture habitual events | Once, to establish the diagnosis | Completed today | Two habitual events with a normal EEG throughout; normal interictal EEG; ILAE 'documented' level |
| Imaging | Brain MRI with an epilepsy protocol | Once, in the diagnostic workup | Completed today | Normal, last week |
| Examination | Event diary: frequency, duration, triggers, warning sensations, and injuries | Every visit | Completed today | Two or three events a month before admission; two recorded on the unit |
| Medication safety | Antiseizure medicine review | At diagnosis and until withdrawn | Completed today | Levetiracetam without benefit and with irritability; taper over three weeks begins today |
| Medication safety | SSRI tolerability check two weeks after starting | 2 weeks after starting and after each dose change | Not indicated | No antidepressant started; psychotherapy first |
| Referral | Neurology consultation (epilepsy and functional neurological disorder) | For recurrent events of uncertain cause | Completed today | Seen on the unit; diagnosis made and explained |
| Referral | CBT-informed psychotherapy for functional seizures | Once the diagnosis is accepted | Ordered | Twelve weekly sessions starting in two weeks |
| Self-management | Driving | Every visit until cleared | Completed today | Not driving; not during the taper; may resume after at least three months free of events, with the neurologist's agreement |
| Self-management | Sleep, studies, and first-aid plan | Every visit | Completed today | Fixed bedtime with at least seven hours; first-aid card for friends and his tutoring workplace |
| Laboratory | Lithium, anticonvulsant mood-stabilizer, or antipsychotic monitoring | Only on those drugs | Not indicated | Not taking any; no bipolar features |
Goal progress:
Guideline basis: CMID: Clinical Monitoring Intelligence Database, depression, bipolar, and mood disorders monograph (2026); LaFrance WC Jr, et al. Minimum requirements for the diagnosis of psychogenic nonepileptic seizures: a staged approach: a report from the International League Against Epilepsy Nonepileptic Seizures Task Force. Epilepsia 2013;54(11):2005-2018 (PMID 24111933) (2013); Hingray C, et al. Functional/dissociative seizures: Proposal for a new diagnostic label and definition by the ILAE task force. Epilepsia 2025;66(11):4162-4182 (PMID 40884444) (2025); Fisher RS, et al. Operational classification of seizure types by the International League Against Epilepsy. Epilepsia 2017;58(4):522-530 (PMID 28276060) (2017); Hall-Patch L, et al. Acceptability and effectiveness of a strategy for the communication of the diagnosis of psychogenic nonepileptic seizures. Epilepsia 2010;51(1):70-78 (PMID 19453708) (2010); Stone J, et al. Explanation as treatment for functional neurologic disorders. Handb Clin Neurol 2016;139:543-553 (PMID 27719870) (2016); LaFrance WC Jr, et al. Multicenter pilot treatment trial for psychogenic nonepileptic seizures: a randomized clinical trial. JAMA Psychiatry 2014;71(9):997-1005 (PMID 24989152) (2014); Goldstein LH, et al. Cognitive behavioural therapy for adults with dissociative seizures (CODES): a pragmatic, multicentre, randomised controlled trial. Lancet Psychiatry 2020;7(6):491-505 (PMID 32445688) (2020); Tolchin B, et al. Seizures, Driver Licensure, and Medical Reporting Update: An AAN Position Statement. Neurology 2025;104(7):e213459 (PMID 40073306) (2025); VA/DoD Clinical Practice Guideline for the Management of Major Depressive Disorder (2022); VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide (2024)
Follow-up: Six-week review; psychotherapy starts in two weeks; call sooner for events that differ from his usual ones, injury, or any thoughts of self-harm. Next scheduled visit 1774-06-11: six-week review after the diagnosis: levetiracetam withdrawn, psychotherapy under way, mood and anxiety. [S]